Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides

E. Chavakis, B. Riecke, J. Lin, T. Linn, R. G. Bretzel, K. T. Preissner, M. Brownlee, H. P. Hammes

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Aims/hypothesis. Vitronectin-receptor-type integrins (αvβ3 and αvβ5) are thought to be involved in the selective ablation of tumorigenic and other pathologic angiogenesis. Specifically, it has been shown that ligation inhibition of the αv-type integrins with cyclic penta-peptid peptide inhibits proliferative retinopathy by almost 80% in a hypoxia-induced mouse model. Methods. On the basis of growth factor and integrin expression dynamics in this model, secondary intervention approaches with cyclic RGDfV peptide were investigated. Results. αv-integrin expression started immediately after induction of hypoxia (at postnatal day 12, p12) and persisted only during the initial period of neovascularization (until day p14). Vascular endothelial growth factor (VEGF) expression started at high values immediately after return of the mice into room air, and dropped rapidly to low values beyond day 13. In contrast, basic fibroblast growth factor (bFGF) was predominantly expressed during the phase of maximum angiogenesis which was noted between day p17 and 19. Based on these findings, cyclic penta peptide was administered subcutaneously at varying doses (2-20 μg/kg/day) for 5 days beginning either at day p14 (early intervention) or at day p17 (late intervention). Early secondary intervention showed a dose-dependent reduction of new vessels with maximum inhibition of 57% (control 68.08 ± 3.21 nuclei/section compared with RGDfV-treated 29.35 ± 2.39 nuclei/section; p < 0.0001), whereas late secondary intervention had no effect. Conclusion/hypothesis. These data indicate that angiogenesis-related αv-integrin expression is VEGF-rather than bFGF-dependent, and the efficacy of cyclic penta-peptid (RGDfV)-treatment in proliferative retinopathy is only effective as long as the αv-integrin target is prominently expressed.

Original languageEnglish (US)
Pages (from-to)262-267
Number of pages6
JournalDiabetologia
Volume45
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Cyclic Peptides
Integrins
Rubiaceae
Fibroblast Growth Factor 2
Vascular Endothelial Growth Factor A
Integrin alphaVbeta3
Pathologic Neovascularization
Ligation
arginyl-glycyl-aspartic acid
cyclic arginine-glycine-aspartic acid peptide
Intercellular Signaling Peptides and Proteins
Air
Peptides

Keywords

  • Alpha-type integrins
  • Basic fibroblast growth factor
  • Endothelial proliferation
  • Microvessels
  • Retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. / Chavakis, E.; Riecke, B.; Lin, J.; Linn, T.; Bretzel, R. G.; Preissner, K. T.; Brownlee, M.; Hammes, H. P.

In: Diabetologia, Vol. 45, No. 2, 2002, p. 262-267.

Research output: Contribution to journalArticle

Chavakis, E, Riecke, B, Lin, J, Linn, T, Bretzel, RG, Preissner, KT, Brownlee, M & Hammes, HP 2002, 'Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides', Diabetologia, vol. 45, no. 2, pp. 262-267. https://doi.org/10.1007/s00125-001-0727-z
Chavakis, E. ; Riecke, B. ; Lin, J. ; Linn, T. ; Bretzel, R. G. ; Preissner, K. T. ; Brownlee, M. ; Hammes, H. P. / Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides. In: Diabetologia. 2002 ; Vol. 45, No. 2. pp. 262-267.
@article{efd1689ac9a540269e8bf71a78d2458b,
title = "Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides",
abstract = "Aims/hypothesis. Vitronectin-receptor-type integrins (αvβ3 and αvβ5) are thought to be involved in the selective ablation of tumorigenic and other pathologic angiogenesis. Specifically, it has been shown that ligation inhibition of the αv-type integrins with cyclic penta-peptid peptide inhibits proliferative retinopathy by almost 80{\%} in a hypoxia-induced mouse model. Methods. On the basis of growth factor and integrin expression dynamics in this model, secondary intervention approaches with cyclic RGDfV peptide were investigated. Results. αv-integrin expression started immediately after induction of hypoxia (at postnatal day 12, p12) and persisted only during the initial period of neovascularization (until day p14). Vascular endothelial growth factor (VEGF) expression started at high values immediately after return of the mice into room air, and dropped rapidly to low values beyond day 13. In contrast, basic fibroblast growth factor (bFGF) was predominantly expressed during the phase of maximum angiogenesis which was noted between day p17 and 19. Based on these findings, cyclic penta peptide was administered subcutaneously at varying doses (2-20 μg/kg/day) for 5 days beginning either at day p14 (early intervention) or at day p17 (late intervention). Early secondary intervention showed a dose-dependent reduction of new vessels with maximum inhibition of 57{\%} (control 68.08 ± 3.21 nuclei/section compared with RGDfV-treated 29.35 ± 2.39 nuclei/section; p < 0.0001), whereas late secondary intervention had no effect. Conclusion/hypothesis. These data indicate that angiogenesis-related αv-integrin expression is VEGF-rather than bFGF-dependent, and the efficacy of cyclic penta-peptid (RGDfV)-treatment in proliferative retinopathy is only effective as long as the αv-integrin target is prominently expressed.",
keywords = "Alpha-type integrins, Basic fibroblast growth factor, Endothelial proliferation, Microvessels, Retinopathy, Vascular endothelial growth factor",
author = "E. Chavakis and B. Riecke and J. Lin and T. Linn and Bretzel, {R. G.} and Preissner, {K. T.} and M. Brownlee and Hammes, {H. P.}",
year = "2002",
doi = "10.1007/s00125-001-0727-z",
language = "English (US)",
volume = "45",
pages = "262--267",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides

AU - Chavakis, E.

AU - Riecke, B.

AU - Lin, J.

AU - Linn, T.

AU - Bretzel, R. G.

AU - Preissner, K. T.

AU - Brownlee, M.

AU - Hammes, H. P.

PY - 2002

Y1 - 2002

N2 - Aims/hypothesis. Vitronectin-receptor-type integrins (αvβ3 and αvβ5) are thought to be involved in the selective ablation of tumorigenic and other pathologic angiogenesis. Specifically, it has been shown that ligation inhibition of the αv-type integrins with cyclic penta-peptid peptide inhibits proliferative retinopathy by almost 80% in a hypoxia-induced mouse model. Methods. On the basis of growth factor and integrin expression dynamics in this model, secondary intervention approaches with cyclic RGDfV peptide were investigated. Results. αv-integrin expression started immediately after induction of hypoxia (at postnatal day 12, p12) and persisted only during the initial period of neovascularization (until day p14). Vascular endothelial growth factor (VEGF) expression started at high values immediately after return of the mice into room air, and dropped rapidly to low values beyond day 13. In contrast, basic fibroblast growth factor (bFGF) was predominantly expressed during the phase of maximum angiogenesis which was noted between day p17 and 19. Based on these findings, cyclic penta peptide was administered subcutaneously at varying doses (2-20 μg/kg/day) for 5 days beginning either at day p14 (early intervention) or at day p17 (late intervention). Early secondary intervention showed a dose-dependent reduction of new vessels with maximum inhibition of 57% (control 68.08 ± 3.21 nuclei/section compared with RGDfV-treated 29.35 ± 2.39 nuclei/section; p < 0.0001), whereas late secondary intervention had no effect. Conclusion/hypothesis. These data indicate that angiogenesis-related αv-integrin expression is VEGF-rather than bFGF-dependent, and the efficacy of cyclic penta-peptid (RGDfV)-treatment in proliferative retinopathy is only effective as long as the αv-integrin target is prominently expressed.

AB - Aims/hypothesis. Vitronectin-receptor-type integrins (αvβ3 and αvβ5) are thought to be involved in the selective ablation of tumorigenic and other pathologic angiogenesis. Specifically, it has been shown that ligation inhibition of the αv-type integrins with cyclic penta-peptid peptide inhibits proliferative retinopathy by almost 80% in a hypoxia-induced mouse model. Methods. On the basis of growth factor and integrin expression dynamics in this model, secondary intervention approaches with cyclic RGDfV peptide were investigated. Results. αv-integrin expression started immediately after induction of hypoxia (at postnatal day 12, p12) and persisted only during the initial period of neovascularization (until day p14). Vascular endothelial growth factor (VEGF) expression started at high values immediately after return of the mice into room air, and dropped rapidly to low values beyond day 13. In contrast, basic fibroblast growth factor (bFGF) was predominantly expressed during the phase of maximum angiogenesis which was noted between day p17 and 19. Based on these findings, cyclic penta peptide was administered subcutaneously at varying doses (2-20 μg/kg/day) for 5 days beginning either at day p14 (early intervention) or at day p17 (late intervention). Early secondary intervention showed a dose-dependent reduction of new vessels with maximum inhibition of 57% (control 68.08 ± 3.21 nuclei/section compared with RGDfV-treated 29.35 ± 2.39 nuclei/section; p < 0.0001), whereas late secondary intervention had no effect. Conclusion/hypothesis. These data indicate that angiogenesis-related αv-integrin expression is VEGF-rather than bFGF-dependent, and the efficacy of cyclic penta-peptid (RGDfV)-treatment in proliferative retinopathy is only effective as long as the αv-integrin target is prominently expressed.

KW - Alpha-type integrins

KW - Basic fibroblast growth factor

KW - Endothelial proliferation

KW - Microvessels

KW - Retinopathy

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=0036189606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036189606&partnerID=8YFLogxK

U2 - 10.1007/s00125-001-0727-z

DO - 10.1007/s00125-001-0727-z

M3 - Article

VL - 45

SP - 262

EP - 267

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 2

ER -